Skip to main content
. 2021 Sep 3;11:651484. doi: 10.3389/fcimb.2021.651484

Figure 1.

Figure 1

Serum markers elevated in COVID-19- and COVID-19+ symptomatic patients compared to healthy controls. The indicated inflammatory markers were assessed by multiplex analysis from the serum of healthy control (HC) volunteers, symptomatic, COVID-19 negative tested patients (CoV-) and symptomatic, COVID-19 positive tested patients (CoV+). For each marker, individual results are depicted as dot plots. Each point represents the median of two technical replicates of each individual. Data are shown on a logarithmic scale for better visualization. Data are shown as median and interquartile range 25%-75%. p > 0.05 = ns not significant; *p < 0.05, **p < 0.01, ****p < 0.0001, Group differences between the three cohorts were tested using Kruskal-Wallis-test in conjunction with Dunn’s multiple comparisons test using multiplicity adjusted calculation of p-values. (HC, n=21), (CoV-, n=16), (CoV+, n=18); APRIL, a proliferation-inducing ligand; sIL-2R-soluble interleukin 2 receptor; IL-7, interleukin 7; MIF, Macrophage migration inhibitory factor; MIP, macrophage inflammatory proteins; SCF, stem cell factor; SDF, 1a-stromal cell-derived factor 1; sTNF, RII-tumor necrosis factor receptor.